Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias
Open Access
- 12 February 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (8) , 1643-1650
Abstract
Background: Early identification of patients at high risk for chemoresistance among those treated with methotrexate (MTX) for low-risk gestational trophoblastic neoplasia (GTN) is needed. We modeled human chorionic gonadotropin (hCG) decline during MTX therapy using a kinetic population approach to calculate individual hCG clearance (CLhCG) and assessed the predictive value of CLhCG for MTX resistance. Patients and methods: A total of 154 patients with low-risk GTN treated with 8-day MTX regimen were retrospectively studied. NONMEM™ was used to model hCG decrease equations between day 0 and day 40 of chemotherapy. Receiver operating characteristic curve analysis defined the best CLhCG threshold. Univariate/multivariate survival analyses determined the predictive value of CLhCG and compared it with published predictive factors. Results: A monoexponential equation best modeled hCG decrease: hCG(t) = 3900 × e−0.149 × t. Median CLhCG was 0.57 l/day (quartiles: 0.37–0.74). Only choriocarcinoma pathology [yes versus no: hazard ratio (HR) = 6.01; 95% confidence interval (CI) 2.2–16.6; P < 0.001] and unfavorable CLhCG quartile (≤0.37 versus >0.37 l/day: HR = 6.75; 95% CI 2.7–16.8; P < 0.001) were significant independent predictive factors of MTX resistance risk. Conclusion: In the second largest cohort of low-risk GTN patients reported to date, choriocarcinoma pathology and CLhCG ≤0.37 l/day were major independent predictive factors for MTX resistance risk.Keywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale to P.G.
This publication has 23 references indexed in Scilit:
- Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomyThe Prostate, 2009
- External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic diseaseBritish Journal of Cancer, 2009
- Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature surveyBritish Journal of Clinical Pharmacology, 2007
- First epidemiological data from the French Trophoblastic Disease Reference CenterAmerican Journal of Obstetrics and Gynecology, 2007
- Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?Clinical Pharmacokinetics, 2007
- Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasiaAmerican Journal of Obstetrics and Gynecology, 2006
- Early Identification of Resistance to First-Line Single-Agent Methotrexate in Patients With Persistent Trophoblastic DiseaseJournal of Clinical Oncology, 2006
- FIGO staging for gestational trophoblastic neoplasia 2000International Journal of Gynecology & Obstetrics, 2002
- hCGbeta core fragment is a metabolite of hCG: evidence from infusion of recombinant hCGJournal of Endocrinology, 2000
- The Population Approach to Pharmacokinetic Data Analysis: Rationale and Standard Data Analysis MethodsDrug Metabolism Reviews, 1984